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In this edition of Haematologica, two papers from the USand Germany report on the long-term follow up ofpatients with multiple myeloma (MM) treated with
reduced intensity conditioning (RIC) and allogeneic
hematopoietic cell transplantation (HCT).1,2 Given the
armamentarium of highly effective agents and a pipeline of
novel therapeutic options, including chimeric antigen recep-
tor T (CAR-T) cells, many hemato-oncologists believe that
there is no longer a role for allogeneic HCT in the treatment
of MM. Despite remarkable improvements in outcomes
with novel drugs, these advances have not yet translated
into cure of the disease, even when combined with high-
dose chemotherapy and autologous HCT. Patients eventu-
ally relapse and die of their underlying disease. The two
reports by Maffini et al. and Greil et al. both show that long-
term survival, and potentially a cure, can actually be
achieved in a proportion of myeloma patients by an allo-
geneic HCT, a treatment outcome that so far has not been
observed with any other therapeutic strategy. 
Maffini et al. present the long-term clinical outcomes of
244 patients who underwent allogeneic HCT following
non-myeloablative conditioning with fludarabine and total
body irradiation (TBI) between 1998 and 2016. In this
study, more than half the patients had a chemotherapy-
based induction with vincristine-doxorubicin-dexametha-
sone (VAD), whereas after 2006 mostly immunomodulato-
ry / proteasome inhibitor triplet regimens were given. The
majority of patients (86%) received tandem autologous-
allogeneic treatment upfront, while 14% had failed previ-
ous autologous HCT. After high-dose melphalan and autol-
ogous HCT, 26% of patients were in a complete remission
(CR), 19% in a very good partial remission (VGPR), 38% in
a partial remission (PR), and 17% had progressive disease.
Best responses following allogeneic HCT were: CR in 46%,
VGPR in 17%, PR in 20% of patients [overall response rate
(ORR) 83%], and 17% failed to achieve a response. With a
median follow up of 8.3 years (range, 1.0-18.1), 5-year over-
all survival (OS) and progression-free survival (PFS) rates
were 54% and 31%, respectively, and 10-year OS and PFS
rates were 41% and 19%, respectively. Non-relapse mortal-
ity was low with 2% at day +100 and 14% at five years,
The rate of acute graft-versus-host disease (GvHD) was
acceptable (33% grade II, 11% grade III / IV), while the
cumulative incidence of chronic GvHD was 46%. The key
findings of this study were: i) that patients with disease that
was refractory to induction and those with high-risk biolog-
ical features experienced shorter OS and PFS, while among
standard-risk patients the median OS was not reached, and
the median PFS was 6.5 years. High-risk patients experi-
enced a median OS of 8.4 years with a PFS of 2.5 years; ii)
patients who proceeded to tandem HCT after a previously
failed autologous HCT had poor outcomes with a median
OS of 1.2 years and a median PFS of 0.4 years; iii) those
patients who achieved negativity for minimal residual dis-
ease (MRD) had a significantly lower relapse rate as com-
pared with MRD-positive (MRD+) patients, indicating that
marrow sampling for MRD assessment post HCT is an
important tool to guide treatment decisions. 
Similar observations were made by Greil et al. who report
on their single center experience of 109 consecutive patients
who received fludarabine-based RIC preparation followed
by allogeneic HCT between 2000 and 2017. With a median
follow up of 71.5 months (6 years), the authors observed a
high ORR of 70% (CR rate 42%), with a median PFS of 14.2
months (1.2 years) and a median OS of 39.2 months (3.3
years). Consistent with the findings of Maffini et al., sur-
vival was better in patients with sufficient response to
induction therapy with a median OS of 65 months (5.4
years vs. 11.5 months in non-responders) and best in those
undergoing allogeneic-HCT within first-line treatment
(median OS not reached vs. 21.6 months in relapsed/refrac-
tory patients). Accordingly, the cumulative incidence of
relapse was considerably lower in patients transplanted in
first-line with 11% within the first year as compared to
50.3% after HCT for relapsed /refractory myeloma. Most
relapses occurred within the first two years post HCT.
Beyond five years, the survival curves appear to have
reached a plateau with late relapses rarely occurring (10-
year OS 28.4% and 10-year PFS 24%). Also in this cohort,
the rate of high-grade GvHD was moderate and the non-
relapse mortality low (8.4% within the first year, 12.4% at
10 years). 
Both the studies by Maffini et al. and Greil et al. provide
evidence that allogeneic HCT can induce graft-versus-
myeloma activity that enables long-term disease control
and survival (potentially even a cure) in selected myeloma
patients. The following observations stand out and require
further reflection and consideration. 
1) Induction treatment in both trials was mostly
chemotherapy-based. The majority of patients achieved
“only” a partial response prior to autologous HCT. Both
studies showed that the depth of response prior to HCT is
critical, and that outcomes in patients who respond to
induction are better when compared with non-responders,
also after allogeneic HCT. Depth of response is a well-
known parameter that predicts clinical outcomes in myelo-
ma, and in recent years MRD testing by PCR or flow
cytometry has become available at many centers. A hall-
mark study underlining the importance of MRD monitor-
ing was presented in a report on the long-term outcomes of
molecular monitoring after a tandem “auto-non-myeloabla-
tive allo” approach.3 Twenty-six patients were prospective-
Editorials
222 haematologica | 2019; 104(2)
The stepchild in myeloma treatments: is allogeneic transplantation not so bad after all?
Antonia M.S. Müller,1 Shaji K. Kumar2 and Benedetto Bruno3
1Department of Medical Oncology and Hematology, University Hospital Zurich, Switzerland; 2Division of Hematology, Mayo Clinic,
Rochester, MN, USA and  3Department of Oncology/Hematology, A.O.U. Città della Salute e della Scienza di Torino, Presidio
Molinette, Torino, Italy
E-mail: benedetto.bruno@unito.it 
doi:10.3324/haematol.2018.206987
ly evaluated by PCR. At a remarkable median follow up of
12.1 years, median OS and EFS were not reached in patients
who achieved nested-PCR negativity while they were 3.3
and 1.5 years, respectively, in the remaining patients. 
Besides the intuitive recognition that “responders do bet-
ter than non-responders”, the biological relevance of
achieving a deep response prior to allogeneic HCT, and
maintaining this response for a certain time post HCT, is
that the establishment of graft-versus-myeloma activity
requires time. In both studies published in this edition of
Haematologica, relapses mostly occurred early, during the
first 1-2 years post allogeneic HCT, reflecting the ongoing
balance between disease biology (aggressiveness) and effec-
tiveness of graft-versus-myeloma activity. The implementa-
tion of novel agents not only prior to HCT, but also post
HCT, likely results in deeper responses prior to HCT and
can help to maintain these responses post allogeneic HCT.
Such strategies may translate into lower relapse rates during
the first year, and thereby provide time for graft-versus-
myeloma effects to establish, particularly once patients are
off immunosuppression. 
2) Both trials clearly indicate that there is anti-myeloma
activity in some patients, as more than 20% were long-term
survivors beyond ten years post HCT. Patients who
relapsed post HCT appeared to have a relatively long sur-
vival, which is consistent with two recently published
reports on long-term follow up post autologous versus autol-
ogous-allogeneic tandem HCT, in which patients post allo-
grafting had a significantly longer OS compared with those
with relapse post autologous HCT.4,5 The question not
answered by the studies published here is whether and
how anti-myeloma activity of donor T cells could be
enhanced in vivo, e.g. by donor lymphocyte infusions (DLI),
immunomodulatory drugs (IMIDs), proteasome inhibitors,
monoclonal antibodies, etc. In both studies, not all patients
had been treated with novel myeloma drugs as induction or
post HCT, in the latter context, mostly for treatment of
active disease. Moreover, at relapse, many patients received
drugs outside the context of clinical trials depending on
which one was readily available at that time. Defined sub-
groups in available studies were thus too small to provide
statistically significant results regarding the impact of novel
therapeutics in general or the influence of a specific drug.
Newer data show that the application of post-HCT borte-
zomib is feasible, safe, and effective even in heavily pre-
treated, poor-risk patients.6,7 IMIDs, in contrast, resulted in
higher toxicity, acute GvHD, and early discontinuation in
one trial,8 whereas in other trials, lenalidomide was given at
lower doses and tolerability was good.9,10
3) The current major cause of treatment failure after allo-
grafting is disease relapse, not treatment-related mortality.
In contrast to early trials, today, under appropriate standard
care, transplant procedures are associated with low toxicity
and GvHD rates are acceptable. In the early 2000s, a num-
ber of trials introduced the tandem approach with an auto-
graft for tumor debulking followed by reduced-intensity or
non-myeloablative allogeneic HCT, a strategy that was able
to lower the toxicity of the regimens. Yet, even today, allo-
geneic HCTs still bear the negative connotation of high tox-
icity, morbidity, treatment-related mortality, and a substan-
tial negative impact on the quality of life. Interestingly,
using the revised Myeloma Comorbidity Index (R-MCI), an
established tool and prognostic instrument for risk predic-
tion in myeloma patients that evaluates renal and lung func-
tion, Karnofksy Performance Status impairment, frailty, and
age,11 Greil et al. showed, that over time, the R-MCI
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Figure 1. Proposed indication for allogeneic (allo)-hematopoietic cell transplantation (HCT) based on studies by Greil et al.,1 Maffini et al.,2 and other authors. 4,7,17
ASCT: autologous stem cell transplantation; DLI: donor lymphocyte infusion, CNI: calcineurin inhibitors; GVHD: graft-versus-host disease; VGPR: very good partial
remission; CAVE: possible adverse effect.
declined through treatment, indicating that performance
status, and accordingly quality of life, was improved by
treating the underlying disease. In those patients whose
condition deteriorated, such a deterioration was from
decreasing renal function and increasing age, and only in a
minority was this due to complications from the allogeneic
HCT, such as chronic GvHD.
Six prospective trials examined the role of allografting
compared with autologous HCT alone.12-21 Substantial dif-
ferences in inclusion criteria and treatment schemas partly
contributed to conflicting outcomes. While most of these
trials demonstrated an improved PFS in the allogeneic
cohort, in only two studies did this response also translate
into a longer OS. Similarly, a meta-analysis of published
clinical trials containing 1192 newly diagnosed patients
who received tandem auto-auto and 630 who underwent
tandem auto-non-myeloablative allogeneic HCT showed
that the CR rates were higher in the auto-allo group, but
there was no survival advantage in the first three years.22 Of
note, the survival advantage in the auto-allo group, reported
in two of the published comparative studies, became statis-
tically significant after a follow up of at least three years. All
these studies were conducted prior to the routine imple-
mentation of novel drugs into induction therapy; treatment
of relapsed disease following HCT varied and was not
taken into consideration when analyzing survival rates.
Today, there is remarkable heterogeneity in the use of
allogeneic HCTs for patients with myeloma among differ-
ent countries, and even institutions, and few ongoing clini-
cal trials are studying how to improve allogeneic HCT
strategies in myeloma or clarify its role. Trends in the use of
HCT in myeloma were published in a large evaluation of
the European Group of Blood and Marrow Transplantation
(EBMT) over a 25-year period that examined a total of 3405
myeloma patients given allogeneic HCT either as an
upfront treatment, within an upfront autologous-allogeneic
HCT concept or as salvage treatment after a failed autolo-
gous HCT.23 It was demonstrated that allogeneic HCT is
currently mostly used as salvage therapy for myeloma
patients after at least one autograft rather than within an
intensified upfront induction-auto-allo approach. Similar to
the studies by Maffini et al. and Greil et al., the EBMT analy-
sis demonstrated that OS rates in the first few years follow-
ing allogeneic HCT were comparable with novel induction
strategies involving new drugs and high-dose chemothera-
py with autologous HCT; however, also in the EBMT
dataset, long-term survival was observed in more than 20%
of patients given allogeneic HCT. Again, patients receiving
allogeneic HCT within an upfront auto-allo tandem
approach achieved better outcomes, but even later trans-
plants, usually in progression or relapse following autolo-
gous HCT, resulted in encouraging long-term outcomes
with 25% survivor rates at ten years. 
In the light of the studies by Maffini et al. and Greil et al.,
and those by other groups, the abandonment of allograft-
ing, as some have suggested, appears rather premature even
in newly diagnosed myeloma patients. The two reports
draw particular attention to the long-term follow up with
potential cure in subsets of patients. Reasons to re-examine
the role of allogeneic HCT for patients with myeloma in
controlled clinical trials are as follows.
• Today, validated tools are available to identify patients
at high risk in whom OS and PFS are very poor even in the
era of new drugs, including the R-MCI,11 the revised
International Staging System by the International Myeloma
Working Group,24 cytogenetics, etc. For this patient subset,
new effective treatments are urgently needed. The negative
prognostic impact of high-risk cytogenetics appeared to be
partly neutralized by graft-versus-myeloma activity in two
recent studies.15,25
• Patient preparation, including the achievement of a
deep response prior to HCT, has significantly improved
over the past decade by incorporating second and third gen-
eration proteasome inhibitors, IMIDs, monoclonal antibod-
ies, and histone deacetylase inhibitors. Patients may, there-
fore, be in better condition (as many of them have not been
exposed to toxic chemotherapy), have improved organ
function, and be in deeper remission of the disease prior to
HCT. These factors all optimize the baseline setting for an
allogeneic HCT, reducing treatment-related toxicity, mor-
bidity, mortality, and providing time for graft-versus-myelo-
ma activity to be established. 
• The role of the combination of new drugs with graft-
versus-myeloma activity has never been systematically
explored in this incurable disease. This may partly be attrib-
uted to the limited current interest on cell therapy strategies
in myeloma. New drugs and graft-versus-myeloma activity
are not mutually exclusive and their synergy has clearly
been shown in relapsed patients. 
In conclusion, despite the recent dramatic improvement
in survival, the overwhelming majority of myeloma
patients invariably relapse. Given the potentially curative
effect of graft-versus-myeloma activity, the role of allograft-
ing should become a matter of sound scientific debate in
the myeloma community. Combinations of allografts with
potent anti-myeloma agents pre- and post-HCT should be
examined in young high-risk and/or early relapsed patients
for whom life expectancy is currently very poor. Modern
MRD monitoring tools may guide individual treatment
decisions and thereby further improve long-term outcomes.
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